Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -780.8%. (2025–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 |
|---|---|---|
| Market Cap | $451331 | — |
| Enterprise Value | $-1023219 | — |
| P/E Ratio → | -0.00 | — |
| P/S Ratio | 0.21 | — |
| P/B Ratio | 0.09 | — |
| P/FCF | — | — |
| P/OCF | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 |
|---|---|---|
| EV / Revenue | — | — |
| EV / EBITDA | — | — |
| EV / EBIT | — | — |
| EV / FCF | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 |
|---|---|---|
| Gross Margin | 39.3% | 39.3% |
| Operating Margin | -750.9% | -750.9% |
| Net Profit Margin | -709.5% | -709.5% |
| Metric | TTM | FY 2025 |
|---|---|---|
| ROE | -780.8% | -780.8% |
| ROA | -341.7% | -341.7% |
| ROIC | -2576.3% | -2576.3% |
| ROCE | -813.1% | -813.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 |
|---|---|---|
| Debt / Equity | 0.10 | 0.10 |
| Debt / EBITDA | — | — |
| Net Debt / Equity | — | -0.76 |
| Net Debt / EBITDA | — | — |
| Debt / FCF | — | — |
| Interest Coverage | — | — |
Net cash position: cash ($2M) exceeds total debt ($193250)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 |
|---|---|---|
| Current Ratio | 0.91 | 0.91 |
| Quick Ratio | 0.87 | 0.87 |
| Cash Ratio | 0.68 | 0.68 |
| Asset Turnover | — | 0.48 |
| Inventory Turnover | 15.43 | 15.43 |
| Days Sales Outstanding | — | 40.55 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 |
|---|---|---|
| Dividend Yield | — | — |
| Payout Ratio | — | — |
| Metric | TTM | FY 2025 |
|---|---|---|
| Earnings Yield | — | — |
| FCF Yield | — | — |
| Buyback Yield | 0.0% | — |
| Total Shareholder Yield | 0.0% | — |
| Shares Outstanding | — | $517671 |
Imminent liquidity and dilution
Based on current market data, BNBX trades at a price-to-sales ratio of 0.24, which appears to reflect a distressed valuation rather than growth potential, as investors heavily discount the firm's ability to convert its specialized mRNA diagnostic pipeline into meaningful, long-term shareholder value.
The low P/S multiple suggests the market is pricing the company as a terminal asset rather than a growth-stage biotech firm. This valuation disconnect implies that the market has largely abandoned expectations for near-term commercial success, viewing the equity primarily as a high-risk option on potential intellectual property liquidation.
As reported in recent financial statements, the company's operating margin of -750.92% highlights a profound inability to scale, with administrative and research overhead vastly outpacing the modest $2.1M revenue base, rendering traditional profitability metrics largely irrelevant for assessing the firm's current earning power.
The extreme disparity between gross and operating margins indicates that the company is burdened by a fixed-cost structure that is far too large for its current diagnostic volume. Investors should monitor whether the firm can achieve any semblance of operating leverage, though current trends suggest that costs are rising faster than the company's ability to capture market share.
According to quarterly filings, the company's cash conversion cycle has remained erratic, swinging from -1394 days in 2024Q3 to -353 days in 2026Q2, which suggests significant friction in collecting payments from third-party payers and managing the underlying laboratory supply chain effectively.
The extreme fluctuations in DSO and DPO indicate that the company lacks a stable relationship with its customers and suppliers, likely due to its early-stage commercial status. This inefficiency in working capital management exacerbates the firm's cash burn, as it is forced to carry significant receivables while struggling to maintain its own liquidity.
Based on the latest quarterly data, the company's current ratio has declined to 1.82, and with cash reserves dwindling to $1.6M, the firm faces an acute liquidity crisis that likely necessitates immediate and potentially dilutive external financing to sustain its ongoing laboratory operations.
The rapid erosion of the cash position relative to the high burn rate suggests that the company is approaching a point of insolvency unless it can secure additional capital. The reliance on equity-based financing appears inevitable, which would further dilute existing shareholders and potentially depress the stock price given the lack of fundamental operational progress.
The price-to-book ratio of 0.10 is frequently misapplied to BNBX, as it erroneously suggests the stock is undervalued, when in reality, the book value is heavily distorted by massive accumulated deficits and a lack of tangible assets capable of generating future cash flows.
Investors should avoid using P/B as a valuation anchor for this business model, as the company's assets are primarily intangible and have not demonstrated the ability to produce returns on capital. A more appropriate focus would be the cash burn rate and the probability of achieving clinical milestones, rather than the accounting value of the firm's depleted balance sheet.
Includes 30+ ratios · 1 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BNBX stock.
BNB Plus Corp.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
BNB Plus Corp.'s return on equity (ROE) is -780.8%.
Based on historical data, BNB Plus Corp. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
BNB Plus Corp. has 39.3% gross margin and -750.9% operating margin.